4sCAR-DLL3 CAR-T therapy
/ SZGIMI
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 19, 2025
DLL3 CAR-T Therapy Targeting Brain Tumors
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute
New P1/2 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • DLL3
1 to 1
Of
1
Go to page
1